



14th European Congress

Heroin Addiction & Related Clinical Problems

European Opioid Addiction Treatment Association - EUROPAD



November 19-21, 2021

University of Grenoble
GRENOBLE
FRANCE-EU

World Trade Center Grenoble
5-7, place Robert Schuman - BP 1521
38025 GRENOBLE CEDEX 1
Phone +33 476 28 28 82
WWW.CONGRES-WTCGRENOBLE.COM

Europad



European Opioid Addiction Treatment Association

AU-CNS

Per aspera ad astra

SINCE 1994

Association for the Application
of Neuroscientific Knowledge
to Social Aims

Affiliated to International Society of Addiction Medicine

European Opioid Addiction Treatment Association

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of non-medical users and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opioid addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

Scientific Committee of GRENOBLE2021EUROPAD

Coordinators

Icro Maremmani (Pisa, Italy)
Marc Reisinger (Brussels, Belgium)

Maurice Dematteis (Grenoble, France)
Andrej Kastelic (Ljubljana, Slovenia)

Local Scientific Committee

Michel Mallaret (Grenoble, France)
Georges Brousse (Clermont-Ferrand)

Lucie Pennel (Grenoble, France)

International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)
Hannu Alho (Helsinki, Finland)
Marc Auriacombe (Bordeaux, France)
Alexander Baldacchino (St Andrews, Scotland, UK)
Barbara Broers (Geneve, Switzerland)
Miguel Casas (Barcelona, Spain)
Thomas Clausen (Oslo, Norway)
Michael Farrell (Sydney, New South Wales, Australia)
Loretta Finnegan (Satellite Beach, Florida, USA)
Gabriele Fischer (Vienna, Austria)
Carla Gambarana (Siena, Italy)
Gilberto Gerra (UNODC)
Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)
Milazim Gjocaj (Pristina, Kosovo)
Liljana Ignjatova (Skopje, Macedonia)
Ante Ivancic (Porec, Croatia)
Minja Jovanovic (Kragujevac, Serbia)
Alexander Kantchelov (Sofia, Bulgaria)
Alexander Kozlov (Moscow, Russia)
Evgeny Krupitsky (St. Petersburg, Russia)

Mercedes Lovrecic (Ljubljana, Slovenia)
Angelo G. I. Maremmani (Viareggio, Italy)
Garrett McGovern (Dublin, Ireland)
Haim Mell (Jerusalem, Israel)
Vladimir Mendelevich (Kazan, Russia)
Genci Mucullari (Tirana, Albania)
Lubomir Okruhlica (Bratislava, Slovak Republic)
Mark Parrino (New York, New York, USA)
Matteo Pacini (Pisa, Italy)
Luis Patricio (Lisbon, Portugal)
Einat Peles (Tel Aviv, Israel)
Giulio Perugi (Pisa, Italy)
Jens Reimer (Hamburg, Germany)
Roncero Alonso Carlos (Salamanca, Spain)
Lorenzo Somaini (Biella, Italy)
Marta Torrens (Barcelona, Spain)
Touzeau Didier (Paris, France)
Albrecht Ulmer (Stuttgart, Germany)
Peter Vossenbergh (Deventer, The Netherlands)
Stephan Walcher (Munich, Germany)

Under the Patronage of

World Federation for the Treatment of Opioid Dependence, New York, NY, USA
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

University of Grenoble, Grenoble, France, EU
Fédération Française d'Addictologie
Mission interministérielle de lutte contre les drogues et les conduites addictives
Fédération Addiction

Promoted by

European Opioid Addiction Treatment Association, Pisa, Italy, EU
Association for the Application of Neuroscientific Knowledge to Social Aims,
Pietrasanta, Italy, EU
Pisa School of Experimental and Clinical Psychiatry, Pisa, Italy, EU

Congress Presidents

MAURICE DEMATTEIS (Grenoble, France, EU)
ICRO MAREMMANI (Pisa, Italy, EU)

Local Scientific Committee

Georges Brousse (Clermont-Ferrand, France, EU)
Michel Mallaret (Grenoble, France, EU)
Lucie Pennel (Grenoble, France)

Venue

World Trade Center Grenoble
5-7, place Robert Schuman - BP 1521
38025 GRENOBLE CEDEX 1
Phone +33 476 28 28 82
WWW.CONGRES-WTCGRENOBLE.COM

Organizing Committee

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Phone +39 0564412038 - Fax +39 0564412485
E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy
Phone +39 0584790073 - Fax +39 058472081
E-mail: info@aucns.org

Europad



European Opioid Addiction Treatment Association

AU-CNS

Per aspera ad astra


SINCE 1994

Association for the Application
of Neuroscientific Knowledge
to Social Aims

Affiliated to International Society of Addiction Medicine

Executive Committee

President



Icro Maremmani
(Italy)

Vice President



Marc Reisinger
(Belgium)

General Secretary



Andrej Kastelic
(Slovenia)



World Federation for the Treatment of Opioid Dependence Executive Committee

President



Icro Maremmani
(Italy)

Vice President



Mark W. Parrino
(USA)

Treasurer



Michael Rizzi
(USA)



Corporate Secretary



Marc Reisinger
(Belgium)

PROGRAM

FRIDAY NOVEMBER 19, 2021

Room and time	ABSTRACT No	
Plenary Room		ORAL PRESENTATIONS
		Europad Oral Presentations <i>Chair: Angelo G. I. Maremmi (Viareggio, Italy, EU)</i>
9:00	OP-1	MARC AURIACOMBE (Bordeaux, France, EU) - Substance Use Disorder Diagnosis and Craving: Comparison of Substance Users Accessing Treatment and Substance Users in Harm Reduction Programs.
9:20	OP-2	ROSHAN BHAD (New Delhi, India) - A Study of Pathways to Care, Stigma and Clinical Correlates of Treatment Seeking Natural Opioid Users in India: Implications for Opioid Crisis Management
9:40	OP-3	PETER ESPENSHADE (Montpellier, USA) - Neither Necessary nor Sufficient, the Role of Peers in the Recovery Workforce
10:00	OP-4	ZOZAN GULEKEN (Istanbul, Turkey) - Spectroscopy and Computer Based Analyse May Be a Tool for Early Diagnose of Inflammation for Opioid Use Disorder Patients
10:20	OP-5	ZUZANA KAMENDY (Bratislava, Slovakia) - Burnout Syndrome in Health Care Professionals in Addiction Treatment
10:40	OP-6	SORAYA MAYET (Hull, UK) - Tele-medicine in Addictions Randomised Controlled Trial
11:00	OP-7	LUCIE PENNEL (Saint-Martin d'Hères, France, EU) - Buprenorphine as a Last Resort Medication for Severe and Treatment Resistant Alcohol-Use Disorder: An Observational Compassionate Study
11:20	OP-8	PERRINE ROUX (Marseille, France, EU) - Individualized Medicine in Harm Reduction : A Step Forward in the Treatment of Addiction
11:40	OP-10	ALBRECHT ULMER (Stuttgart, Germany, EU) - Dihydrocodeine Vs. Acamprosate for the Medical Adjustment of Alcohol Dependent Patients

FRIDAY NOVEMBER 19, 2021

Room and time	ABSTRACT No	
Plenary Room		EUROPAD PRE-CONGRESS SYMPOSIUM
		1 - INTERNET PROBLEMATIC USE IS ASSOCIATED WITH PSYCHOPATHOLOGY SPECIFIC OF SUBSTANCE USE DISORDER <i>Chair: Liljana Ignjatova (Skopje, North Macedonia)</i>
	12:00	SE1-1 LILJANA IGNJATOVA (Skopje, North Macedonia) - Problematic Internet Use Among Youngsters
	12:20	SE1-2 CATERINA FLORA (Paphos, Cyprus, EU) - European Network For Problematic Internet Use: Citizens Involvement. A Pilot Study In Parents, In Greece
12:40	SE1-3 FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Internet Problematic Use Is Associated with Psychopathology Specific of Substance Use Disorder	
Plenary Room		EUROPAD LUNCH SPECIAL CONFERENCE
		FRONTIERS IN ADDICTION MEDICINE <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
	13:00	SE2-1 MARC REISINGER (Brussels, Belgium, EU) - Climate Anxiety and Addictive Behaviours
EUROPAD SPECIAL EVENTS		
Plenary Room		EUROPAD SPECIAL CONFERENCE funded by industry
		1 - LEVO-METHADONE IN ITALY <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
	13:30	SE3-1 MARCO RIGLIETTA (Bergamo, Italy, EU) - LEVOPROACT: post-marketing surveillance in Italy
Plenary Room		SPECIAL EVENTS funded by industry
		2 - SHIFTING PARADIGMS: CLINICAL EXPERIENCE OF LONG-ACTING FORMULATIONS <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>
	14:00	SE4-1 ICRO MAREMMANI (Pisa, Italy, EU) - Is the Agonist Opioid Treatment Long Enough? The Role of Long-acting Medications
	14:20	SE4-2 LORENZO SOMAINI (Biella, Italy, EU) - Understanding long-acting formulations
	14:40	SE4-3 ARUN DHANDHAYUDHM (London, UK) - Experience of using long-acting formulations in UK
	15:00	SE4-4 DAN LUBMAN (Richmond, Victoria, Australia) - Experience of using long-acting formulations in Australia
		3 - BEYOND THE PILL: FUTURE DIRECTIONS IN THE TREATMENT OF OPIOID USE DISORDER (OUD) <i>Chair: Lorenzo Somaini (Biella, Italy, EU)</i>
	15:30	SE5-1 LORENZO SOMAINI (Biella, Italy, EU) - Moving Towards an Evidence Based Approach in OUD
	16:00	SE5-2 LUKE MITCHESON (London, UK) - Improving patient outcomes through effective PSIs
	16:30	SE5-3 MARK GILMAN (Manchester, UK) - A holistic approach to optimising patient recovery

FRIDAY NOVEMBER 19, 2021

ABSTRACT

Plenary Room		PLENARY SESSION 1 <i>Chair: Icro Maremmanni (Pisa, Italy, EU) - Maurice Dematteis (Grenoble, France, EU)</i>
17:15		ICRO MAREMMANI (Pisa, Italy, EU) & MAURICE DEMATTEIS (Grenoble, France) - Conference Opening
17:30	PL-1	MARK PARRINO (New York, NY, USA) - Evolving Policy Issues with Opioid Use Disorder in the United States
18:00	PL-2	Sir JOHN STRANG (London UK) - Treatment of Opioid Use Disorder: Three Lessons to Learn from the Past and Changes We Must Make for a Better Future
19:00	PL-3	MAURICE DEMATTEIS (Grenoble, France, EU) - From Categories to Dimensions in Addiction Medicine and Mental Health: A Pragmatic Approach to Treat Patients from Harm Reduction to Recovery
20:00		BREAK
20:30		WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2020- THE ALESSANDRO TAGLIAMONTE AWARD <i>Chairs: Icro Maremmanni (Pisa, Italy, EU) - Marc Reisinger (Brussels, Belgium, EU) Andrej Kastelic (Ljubljana, Slovenia, EU)</i>

TO BE AWARDED: STEPHAN WALCHER (Munich, Germany)

GENCI MUCOLLARI (Tirana, Albania)

ANGELO G.I. MAREMMANI (Viareggio, Italy)

CAREER AWARD: HERMAN JOSEPH (New York, NY, USA) - To memory



CHIMERA AWARD
European Opiate Addiction Treatment Association Award
"The Alessandro Tagliamonte Award"
"Dedicated to all those who dream of a better world for drug addicts"

21:30		CONCERT IN HONOUR OF ROBERT NEWMAN Robert-Newman-Trio, a composition of Albrecht Ulmer Andrey Khvostenko, violin Marcin Niziol, viola Albrecht Ulmer, piano forte
-------	--	--

Dr. Robert Newman (1937 - 2018) was like a good father and friend for many of us. He was the former president of the Beth Israel Medical center in New York, where the Methadone maintenance therapy was developed by Mary Nyswander and Vincent Dole. Later, from 2001–2013, he worked as director of the Baron Edmond de Rothschild Chemical Dependency Institute of BIMC. He counseled innumerable experts and governments whole over the world how to implement the treatment with Methadone. Many called him "Methadone-pope", and he joked: I'm the only Jewish pope of the world. He was a real and personal friend for many of us. This is specially to mention towards Germans, because his grandfather Feilchenfeld was killed in a concentration camp by the Nazis (Feilchenfeld-subject in the final movement of the trio). But Robert was one of most wise persons of the world, never asking for any guilt, but interested in everybody, always open for a warm hearted friendship. He never asked: How important is this person for me? He encouraged many of us, who elsewhere experienced several disregards from leading experts, because they where no leading or established persons. His sensibility for the dignity of broken and especially addicted patients was unique. Many of us are influenced by this particular humanity in our daily work with the addicted patients for ever.

SATURDAY NOVEMBER 20, 2021

Room and time	ABSTRACT No	
9:00		PARALLEL SYMPOSIA
Plenary Room		1 - PAIN PSYCHIATRIC DISORDERS AND ADDICTIVE DISORDERS: GROWING EPIDEMIOLOGY AND COMMON PATHOPHYSIOLOGY PLEAD FOR INTEGRATED APPROACHES <i>Chair: Rolland Benjamin (Bron, France, EU)</i>
9:00	S01-1	GEORGES BROUSSE (Clermont-Ferrand, France, EU) - Type of Pain (Dolorosa) Matters: Physical or Mental, but the Human Partition Remains the Same
9:30	S01-2	MAURICE DEMATTEIS (Grenoble, France, EU) - Addictive, Psychiatric and Pain Disorders: Different Clinical Expressions but Final Common Pathways
10:00	S01-3	MARK KRAUS (New Haven, CT, USA) - Prevention, Diagnosis, and Management of Prescription Opioid Use Disorder: Consensus and Controversies between European Pain and Addiction Specialists
Room A		2 - POTENTIAL ADVANCES IN METHADONE-BASED TREATMENT FOR OPIOID USE DISORDER <i>Chair: Sergi Ferré (Baltimore, MD, USA)</i>
9:00	S02-1	SERGI FERRÉ (Baltimore, MD, USA) - Opioid-Galanin Receptor Heteromers Determine Weaker Dopaminergic Effects of Methadone as Compared to Morphine and Fentanyl
9:30	S02-2	ANNABELLE BELCHER (Baltimore, MI, USA) - Harnessing Placebo Effects to Augment Methadone Treatment Retention
10:00	S02-3	DECLAN T. BARRY (New Haven, CT, USA) - Scale Up of Methadone Maintenance Treatment Using an Open-Access Model
Room B		3 - DIFFERENT CLINICAL APPROACHES TO REACH PERSONS WITH OPIOID USE DISORDER; HOW TO BEST ADAPT TO CHANGING PATIENTS' NEEDS <i>Chair: Thomas Clausen (Oslo, Norway) - Gabriele Fisher (Vienna, Austria, EU)</i>
9:00	S03-1	MARC AURIACOMBE (Bordeaux, France, EU) - The France Experience with Primary Care Level Provision of Buprenorphine for OUD as the Main Approach
9:20	S03-2	GABRIELE FISCHER (Vienna, Austria, EU) - Slow Release Oral Morphine (SROM) as the Preferred Treatment for OUD: The Austrian Experience
9:40	S03-3	LARS TANUN (Oslo, Norway) - Long-Acting Injectable Partial Agonist and Antagonists: Promises and Pitfalls of Long-Acting Injectable for OUD
10:00	S03-4	THOMAS CLAUSEN (Oslo, Norway) - A Range of Clinical Approaches to Reach Persons with Opioid Use Disorder Within One Clinic
Room C		4 - VULNERABILITY TO ADDICTION <i>Chair: David Belin (Cambridge, UK)</i>
9:00	S04-1	ALEJANDRO HIGUERA-MATAS (Valencia, Spain, EU) - Opioid Self-Administration Alters Brain Neurochemistry and Neural Plasticity Mediators: Modulation Following Withdrawal or Extinction.
9:20	S04-2	LUCIA HIPOLITO (Madrid, Spain, EU) - Inflammatory Pain Induces Dysregulation of the KORS and MORS within Mesocorticolimbic System: Impact on Heroin and Alcohol Self-Administration
9:40	S04-3	BENJAMIN BOUTREL (Prilly, Switzerland) - The Olievenstein's broken mirror theory revisited: earlier life matters, how and why
10:00	S04-4	DAVID BELIN (Cambridge, UK) - Behavioural and Neural Basis of the Individual Vulnerability to Develop Compulsive Heroin Seeking Habits
10:30		COFFEE BREAK
Plenary Room		Round Table - New perspectives of depot medications in Heroin Use Disorder <i>Chair: Icro Maremmani (Pisa, Italy)</i>
11:00	PS4	MICHAEL FROST (Conshohocken, PA, USA) - DAN LUBMAN (Richmond, Victoria, Australia) - VIJAY NADIPELLI (Richmond, VA, USA) - MAURICE DEMATTEIS (Grenoble, France, EU) - LORENZO SOMAINI (Biella, Italy, EU) -
13:00		CONFERENCE LUNCH

SATURDAY NOVEMBER 20, 2021

Room and time	ABSTRACT No	
Plenary Room		PLENARY SESSION 2 <i>Chair: Jean-Pierre Daulouede (Bayonne, France, EU)</i>
14:00	PL-4	MICHAEL FINGERHOOD (Baltimore, PA, USA) - Substance Use Disorders in Later Life
15:00		PARALLEL SYMPOSIA
Plenary Room		5 - THE EUROPEAN ADDICTOVIGILANCE NETWORK: ROLE IN THE OPIOID EPIDEMICS AND IN OPIOID USE DISORDER WITH COMORBIDITIES (PAIN AND DUAL DISORDER) <i>Chair: Michelle Mallaret (Grenoble, France, EU)</i>
15:00	S05-1	MICHELLE MALLARET (Grenoble, France, EU) - The European Addictovigilance Network: Functioning and Role in the Epidemics of Opioid Substances and Their Regulation
15:30	S05-2	JOELLE MICALLEF (Marseille, France, EU) - Opioid Addiction in No-Cancer Chronic Pain Patients: Results from the French Addictovigilance Network
16:00	S05-3	MARYSE LAPEYRE-MESTRE (Toulouse, France, EU) - Opioid Addiction in ADHD Patients: Results from the French Addictovigilance Network
Room A		6 - USE OF PSYCHIATRIC MEDICATIONS IN DUAL DISORDER HEROIN USE DISORDER PATIENTS (in collaboration with World Association on Dual Disorder - WADD) <i>Chair: Nestor Szerman (Madrid, Spain, EU)</i>
15:00	S06-1	NESTOR SZERMAN (Madrid, Spain, EU) - Opioid System and Mental Disorder
15:30	S06-2	ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Mood Disorders) Patients
16:00	S06-3	ICRO MAREMMANI (Pisa, Italy, EU) - Use of Psychiatric Medications in Dual Disorder (Heroin Use Disorder/Psychotic Disorder) Patients
Room B		7 - SEEA NET SYMPOSIUM: PATIENTS TAILORED PROGRAMS - REALITY OR WISH (in collaboration with the South Eastern European and Adriatic Addiction Treatment Network) <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
15:00	S07-1	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Between Patients Needs, Expectations, Guidelines, Regulations and Law
15:30	S07-2	MIRJANA DELIC (Ljubljana, Slovenia, EU) - Different Dimensions of Wellness as a Part of Drug Addiction Treatment
16:00	S07-3	NUSA SEGREC (Ljubljana, Slovenia, EU) - Treat or Not to Treat - Is This a Question?
Room C		8 - SELECTED EUROPAD PRESENTATIONS <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
15:00	S08-1	MARC AURIACOMBE (Bordeaux, France, EU) - Buprenorphine Dose, Craving and Opioid Use Severity in a Naturalistic Treatment Setting
15:30	S08-2	PAOLA ROSCA (Jerusalem, Israel) - Suboxone Film in Opioid Maintenance Treatment Centers: The Israeli Pilot Study Experience
16:00	S08-3	GABRIELLE KATRINE WELLE-STRAND (Oslo, Norway) - Somatic and Mental Health of Women in Opioid Maintenance Treatment (OMT) 10 Years after Their Child Was Born
16:30		COFFEE BREAK

SATURDAY NOVEMBER 20, 2021

Room and time	ABSTRACT No	
Plenary Room		PLENARY SESSION 3 <i>Chair: - Jean Jacques Deglon (Geneve, Switzerland)</i>
17:00	PL-5	YIFRAH KAMINER (Farmington, CT, USA) - Determining Youth Intentional Lethal Opioids Over Dose: The Case of Psychological Autopsy to Complement the Medical Examiner Report
18:00		PARALLEL SYMPOSIA
Plenary Room		9 - HARM REDUCTION AS A KEY PRINCIPLE FOR ACCESS TO CARE: INSIGHTS FROM THE SWISS-ROMANDY COLLEGE OF ADDICTION MEDICINE <i>Chair: Olivier Simon (Lausanne, France, EU)</i>
18:00	S09-1	GERARD CALZADA (Geneve, Switzerland) - Prescription of Pharmaceutical Heroin Versus a Safe Place for Consumption
18:30	S09-2	OLIVIER SIMON (Lausanne, France) - Applying Risk and Harm Reduction to Gambling?
19:00	S09-3	DANIELE ZULLINO (Geneve, Switzerland) - From Heroin to Medical and No-Medical Cannabis
Room A		10 - UNDERSTANDING THE CURRENT OPIOID CRISIS: GLOBAL CRISIS OF NO-MEDICAL USE OF OPIOIDS <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
18:00	S10-1	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Outbreak of 'Novel Synthetic Opioids': No-Medical Use of Opioids
18:30	S10-2	MICHAEL J. BANNON (Detroit, MI, USA) - Decision Tree Analysis Reveals Recent Trends, Bio-markers, and Potential Drug Interactions Associated With Opioid Abuse
19:00	S10-3	MAREN WRIGHT VOSS (Salt Lake City, UT, USA) - A Pain Education and Opioid Monitoring Program for a Community Setting: Creating Safety and Screening around Prescribed Opioids
Room B		11 - INTEGRATED PSYCHIATRIC REHABILITATION FOR PATIENTS WITH DUAL DISORDERS: TOWARDS SOCIAL AND PERSONAL RECOVERY <i>Chair: Julien Dubreucq (St Martin d'Hères, France, EU)</i>
18:00	S11-1	JULIEN DUBREUCQ (St Martin d'Hères, France, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in France: The Experience from Grenoble
18:30	S11-2	YASSER KHAZAAL (Lausanne, Switzerland, EU) - Recovery-Oriented Treatment for Patients with Dual Disorders in Switzerland: The Experience from Lausanne
19:00	S11-3	KIM MUESER (Boston, MA, USA) - Recovery-Oriented Treatment for Patients with Dual Disorders in the USA: The Experience from Boston
Room C		12- ADDICTION, INFECTIOUS DISEASES, ETHIC: HEALTHCARE IN PRISON <i>Chair: Fadi Meroueh (Montpellier, France, EU)</i>
18:00	S12-1	FADI MEROUEH (Montpellier, France, EU) - Elimination of Hepatitis C in Prison: Essential Combination Treatment with Harm Reduction
18:30	S12-2	ROBERT TELTZROW (Paris, France, EU) - New Psychoactive Substances in Prison – an Incalculable Risk for European Prisons?
19:00	S12-3	LINDA MONTANARI (Lisbon, Portugal, EU) - Drug Related Interventions in Europeans Prison: Evidence and Availability
20:30		SPEAKERS' DINNER*
		* Tickets are available for all delegates

SUNDAY NOVEMBER 21, 2021

Room and time	ABSTRACT No	
9:00		PARALLEL SYMPOSIA
Plenary Room		13 - SUBSTANCE USE AND HUMAN RIGHTS <i>Chair: Marta Torrens (Barcelona, Catalonia, Spain)</i>
9:00	S13-1	PETER KASTNER (Vienna, Austria, Eu) - Monitoring Human Rights Under the National Prevention Mechanism (NPM) Including Nelson Mandela Rules
9:30	S13-2	LINDA MONTANARI (Lisbon, Portugal, EU) - HCV in Europeans Prison in Persons with Drug Related Problems
10:00	S13-3	GABRIELE FISCHER (Vienna, Austria) - Hepatitis C and Attention-Deficit Hyperactivity Disorder in a High-Risk Group of Opioid-Maintained Prisoners
Room A		14 - BENZODIAZEPINE USE AND ABUSE IN OPIOID AGONIST TREATMENT <i>Chair: Martin Haraldsen (Sandefjord, Norway)</i>
9:00	S14-1	MARTIN HARALDSEN (Sandefjord, Norway) - Benzodiazepine Stabilisation Treatment (BST) in Conjunction with Opioid Agonist Treatment (OAT): The Experience from a Norwegian Town General Practice Supporting BST
9:30	S14-2	ADAM BAKKER (London, Uk) - Benzodiazepine Maintenance in Opioid Agonist Treatment (OAT), Good or Bad?
10:00	S14-3	FERGUS LAW (Bath, Uk) - Opioid Overdose and a New Model of Drug Use and Tolerance with Implications for Treatment
Room B		15 - METHADONE-ASSISTED PSYCHOTHERAPY (in collaboration with the Kantchelov Clinic) <i>Chair: Alexander Kantchelov (Sofia, Bulgaria)</i>
9:00	S15-1	RICK BES (Hilversum, Netherlands, EU) - Facilitating Change: Implementation of Mi (Motivational Interviewing) in Methadone-Assisted Psychotherapy
9:30	S15-2	TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - From Specific Psychopathology Towards Psychotherapeutic Strategies in Opioid Addiction Treatment
10:00	S15-3	ROBERT LAMBERT (Waterbury, Connecticut, USA) - Increasing Retention in Comprehensive Methadone Treatment by Integrating a Patient Centred Approach
10:30		COFFEE BREAK
Plenary Room		PLENARY SESSION 4 <i>Chair: Amine Benyamina (Paris, France, EU)</i>
11:00	PL-6	PIER PAOLO PANI (Cagliari, Italy, EU) - Unitary View of Psychopathology of Addiction. From Neurobiology to Clinical Perspective
12:00	PL-7	IVAN MONTOYA (Rockville, Maryland, USA) - Therapeutic Perspective of Opioid Partial Agonists in Addiction Medicine and Psychiatric Disorders
		 <p>ROVAI SCHOLARS AWARD PISA-School of Clinical and Experimental Psychiatry Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) "The Luca Rovai Award" "Dedicated to all those who dream of a better world for drug addicts"</p>
13:00		Best poster Rovai Scholars award
13:15		ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Pisa, Italy, in May 20-22, 2022!



POSTER SESSION

ABSTRACT

No

P-01	CHRISTER AAS (Bergen, Norway) - Quality of Life among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study
P-02	SEKER BURCU CETIN (Üsküdar, İstanbul Turkey) - Opioid Use of the Patients Who Have Both Addiction and a Risk of Ptsd in an Addiction Outpatient Counseling Center
P-03	LARS T. FADNES (Bergen, Norway) - Effect of Integrated Treatment of Hepatitis C among People with Opioid Addiction: Results from a Multicenter Randomised Controlled Trial
P-04	MOHAMED FARAH et al. (Massy, France, EU) - Risk-Adjusted Abstinence Rates Are Higher with Greater Buprenorphine Plasma Exposure among Patients Who Inject Opioids
P-05	DIMY FLUYAU (Tyrone, GA, USA) - N-Methyl-D-Aspartate Receptor Antagonists for Opioid Dependence
P-06	FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain) - A Multidisciplinary Approach to Treat Hepatitis C Infection in Heroin Addicted Patients
P-07	FRANCINA FONSECA et al. (Barcelona, Catalonia, Spain, EU) - Reaching the 90-90-90 UNAIDS Treatment Target for People Who Inject Drugs Receiving Integrated Clinical Care in a Drug Use Outpatient Treatment Facility
P-08	ALLISON GALLANT (Saint John, Canada) - Prevalence and Trends of Illicit Drug Use and Retention in a Low Threshold/High Tolerance Methadone Maintenance Treatment Program
P-09	AARON GREENBLATT (Baltimore, MD, USA) - Race-Based Differences in Self-Reported Drug Use at an Urban Methadone Treatment Program
P-10	ZHANNA GAULEN et al. (Bergen, Norway) - Changes in Life Satisfaction among Opioid-Dependent Individuals Treated with Extended-Release Naltrexone or Buprenorphine-Naloxone
P-11	MARGAUX KOSIM et al. (Paris, France, EU) - Patient Acceptance and Willingness to Use a New Formulation of Long Acting Buprenorphine- AMBRE Survey Results
P12	JIMMY LANGLOIS et al. (Quebec, Canada) - Psychosocial outreach during outpatient low-barrier detoxification process with vulnerable people disaffiliated from formal health care system
P-13	AMANDA LIBERMAN et al.(New Haven, CT, USA) - Decisional considerations for methadone uptake In Kyrgyz prisons
P-14	MERCEDES LOVRECIC et al. (Ljubljana, Slovenia, EU) - The Filing of Addicted Patients at Addiction Units Is Correlated with a Reduction in Mortality Due to Illicit Opioids, but Also to Prescribed Opioids and Other Abused Substances
P-15	NERMANA MEHIĆ-BASARA et al. (Sarajevo, Bosnia and Herzegovina) - Somatic Complications in Homeless Heroin Addict in the AOT Program - Case Report
P-16	PASCAL MELIN et al. (Saint Dizier, France, EU) - The Right Patient in the Right Way: “Road trip Hépatant”
P-17	KALIA NIKOLAU (Limassol, Cyprus, EU) - The Role of Dynamic Inter-Family Characteristics in Drug Addiction
P-18	WALTER PAGANIN et al. (Tivoli (RM), Italy, EU) - Depression Resistant to Antidepressant Medications or Depression Complicated by Hypophoria? (a Case Report)
P-19	GABRIEL SHAYA et al. (Slough, UK) - Reducing Relapse with Buprenorphine: Findings from the COSTEDOPIA & German Real-World Studies
P-20	MARIA GIOVANNA TOCCO et al. (Milan, Italy, EU) - High Therapeutic Buprenorphine Levels Reduce Iv Fentanyl Respiratory Depression

P-21	JOAN TRUJOLS et al. (Barcelona, Catalonia, Spain, EU) - Towards a Common Metric for Assessing Heroin-Dependent Patient Satisfaction with Medications: Satisfaction with Methadone as a Gold Standard?
P-22	JOAN TRUJOLS et al. - Quality of Life and Well-Being from the Perspective of Patients on Opioid Agonist Maintenance Treatment: A Synthesis of Qualitative Research
P-23	ALBRECHT ULMER (Stuttgart, Germany, EU) - Quintessence: What Have I Learned in the 30 Years of Treatment of Addicted Patients?
P-24	ALBRECHT ULMER (Stuttgart, Germany, EU) - The Nonsense and Crime of Prohibition
P-25	GABRIEL VALLECILLO et al. (Barcelona, Catalonia, Spain, EU) - Increased Cardiovascular Risk among Older Adults with Heroin Use Disorder: A Comparative Study with the Population-Based REGICOR Cohort
P-26	JORN HENRIK VOLD (Bergen, Norway) - Mental Health Symptoms among People with Opioid Dependence: Results from a Multicenter Nested Cohort Study

Faculty

Christer AAS	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: christer.frode.aas@helse-bergen.no]
Marc AURIACOMBE	University of Bordeaux, Bordeaux, France, EU - [E-Mail: marc.auriacombe@u-bordeaux.fr]
Adam BAKKER	Lisson Grove Health Centre, NHS, London, UK - [E-Mail: bakkerismo@gmail.com]
Michael J. BANNON	Wayne State University School of Medicine, Department of Pharmacology, Detroit, MI, USA - [E-Mail: mbannon@med.wayne.edu]
Declan T. BARRY	Yale University School of Medicine, New Haven, CT, USA - [E-Mail: declan.barry@yale.edu]
Annabelle BELCHER	University of Maryland School of Medicine, Baltimore, ML, USA - [E-Mail: abelcher@som.umaryland.edu]
David BELIN	University of Cambridge, Department of Psychology, Cambridge, UK - [E-Mail: bdb26@cam.ac.uk]
Rolland BENJAMIN	Service Universitaire d'Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: Benjamin.ROLLAND@ch-le-vinatier.fr]
Rick BES	Centre for Motivation and Change, Hilversum, Netherlands, EU - [E-Mail: rikbes@me.com]
Roshan BHAD	All India Institute of Medical Sciences (AIIMS), New Delhi, India - [E-Mail: drroshansindia@gmail.com]
Benjamin BOUTREL	Lab on the Neurobiology of Eating and Addictive Disorders, CHUV-Department of Psychiatry, Prilly, Switzerland - [E-Mail: benjamin.boutrel@unil.ch]
Georges BROUSSE	Service Universitaire d'Addictologie de Lyon (SUAL), Ch Le Vinatier, Lyon University Hospital, Bron, France, EU - [E-Mail: gbrousse@chu-clermontferrand.fr]
Seker BURCU CETIN	Turkish Green Crescent Society Counseling Center, Üsküdar, İstanbul Turkey - [E-Mail: burcu.cetin@yesilay.org.tr; burcucetin@windowslive.com]
Gerard CALZADA	Service d'addictologie des HUG and College Romand de Médecine de l'Addiction, Geneve, Switzerland - [E-Mail: Gerard.Calzada@hcuge.ch]
Thomas CLAUSEN	Oslo University Hospital, Oslo, Norway - [E-Mail: thomas.clausen@medisin.uio.no]
Mirjana DELIC	Ljubljana, Slovenia, EU - [E-Mail: mirjana.delic@psih-klinika.si]
Filippo DELLA ROCCA	School of Psychiatry, University of Pisa Pisa, Italy, EU - [E-Mail: filippo.dellarocca@yahoo.it]
Maurice DEMATTEIS	Grenoble Alpes University Hospital, Grenoble, France, EU, Grenoble, France, EU - [E-Mail: MDematteis@chu-grenoble.fr]
Arun DHANDAYUDHAM	Westminster Drug Project - WDP, London, UK - [E-Mail: arun.dhandayudham@wdp.org.uk]
Julien DUBREUCQ	Centre Référent de Réhabilitation Psychosociale et de Remédiation cognitive, St Martin d'Hères, France, EU - [E-Mail: jdubreucq@ch-alpes-isere.fr]
Peter ESPENSHADE	Recovery Vermont, Montpelier, USA - [E-Mail: peter@recoveryvermont.org]
Lars T. FADNES	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway - [E-Mail: Lars.Fadnes@uib.no]
Mohamed FARAH	Indivior France, Massy, France, EU - [E-Mail: mohamed.farah@indivior.com]
Sergi FERRÉ	National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD, USA - [E-Mail: sferre@intra.nida.nih.gov]
Michael FINGERHOOD	Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Bayview Hospital Medical Center, Baltimore, Maryland, USA - [E-Mail: mifinger@jhmi.edu]

Gabriele FISCHER	Department for Psychiatry & Psychotherapy, Medical University Vienna, EU, Austria - [E-Mail: gabriele.fischer@meduniwien.ac.at]
Caterina FLORA	Clinical Psychology, Paphos, Cyprus, EU, Paphos, Cyprus, EU - [E-Mail: k.flora@nup.ac.cy]
Dimy FLUYAU	Emory University- School of Medicine, Tyrone, GA, USA - [E-Mail: dimy.fluyau@emory.edu]
Francina FONSECA	Institute of Neuropsychiatry and Addictions (INAD), Hospital del Mar Medical Research Institute-IMIM. Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: mfonseca@parcdesalutmar.cat]
Michael FROST	Frost Medical Group, Conshohocken, PA, USA - [E-Mail: drfrost@verizon.net]
Allison GALLANT	Dalhousie University, Horizon Health Network, Saint John, Canada, Saint John, Canada - [E-Mail: allison.gallant@dal.ca]
Zhanna GAULEN	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. The University of Bergen, Bergen, Norway - [E-Mail: zhanna.gaulen@helse-bergen.no]
Aaron GREENBLATT	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: agreenbl@som.umaryland.edu]
Mark GILMAN	Discovering Health Ltd, Manchester, UK - [E-Mail: mark.gilman@discoveringhealth.com]
Zozan GULEKEN	Üsküdar University, Istanbul, Turkey - [E-Mail: zozanguleken@gmail.com]
Martin HARALDSEN	Sandefjord, Norway - [E-Mail: martinharaldsen@outlook.com]
Alejandro HIGUERA-MATAS	Dpt. Farmàcia I Tec. Farmacèutica, Facultat Farmàcia, Universitat de València Valencia, Spain, EU - [E-Mail: ahiguera@psi.uned.es]
Lucia HIPOLITO	Department of Psychobiology. School of Psychology. National University for Distance Learning (UNED), Madrid, Spain., EU - [E-Mail: lucia.hipolito@uv.es]
Liljana IGNJATOVA	University Psychiatric Clinic, Skopje, North Macedonia - [E-Mail: liljana.kitevaignjatova@yahoo.com]
Zuzana KAMENDY	Centre for Treatment of Drug Dependencies, Bratislava, Slovakia - [E-Mail: zuzana.kamendy@gmail.com]
Yifrah KAMINER	Alcohol Research Ctr at the University of Connecticut Medical School, Farmington, CT, USA - [E-Mail: Kaminer@psychiatry.uchc.edu]
Alexander KANTCHELOV	The Kantchelor Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelor@gmail.com]
Andrej KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER	Ombudsmen Institute, Vienna, Austria, EU - [E-Mail: peter.kastner@volksanwaltschaft.gv.at]
Yasser KHAZAAL	Service de Médecine des Addictions, Lausanne, France, EU - [E-Mail: yasser.khazaal@chuv.ch]
Margaux KOSIM	Consultation Addictologie Pass Hopital Pitié Salpêtrière, Paris, Ile De France, France, EU - [E-Mail: margaux.kosim@camurus.com]
Mark KRAUS	Yale University School of Medicine Connecticut, New Haven, CT, USA - [E-Mail: markk@cox.net]
Robert LAMBERT	Connecticut Counseling Centers, Inc., Waterbury, Connecticut, USA - [E-Mail: rlambert@ctcounseling.org]
Jimmy LANGLOIS	Université Laval, Québec, Canada - [E-Mail: jimmy.langlois.1@ulaval.ca]
Maryse LAPEYRE-MESTRE	Addictovigilance, Toulouse, France, EU - [E-Mail: maryse.lapeyre-mestre@univ-tlse3.fr]
Fergus LAW	University of Bristol, Bath, UK - [E-Mail: fergus.law1@gmail.com]

Amanda LIBERMAN	Yale University, New Haven, CT, USA
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Dan LUBMAN	Turning Point, Eastern Health and Monash Addiction Research Centre, Monash University, Richmond, Victoria, Australia - [E-Mail: dan.lubman@monash.edu]
Michelle MALLARET	Centre Addictovigilance CHU, Grenoble, France, EU - [E-Mail: mmallaret@chu-grenoble.fr]
Angelo G. I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Viareggio, Italy, EU - [E-Mail: angelogimaremmanni@gmail.com]
Icro MAREMMANI	Vincent P. Dole Dual Disorder Unit, 2nd Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmanni@med.unipi.it]
Soraya MAYET	Humber Teaching NHS FT, Hull, UK, Hull, UK - [E-Mail: smayet@nhs.net]
Nermana MEHIĆ-BASARA	Public Institute for Addiction Disorders of the Canton of Sarajevo, Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina - [E-Mail: zalcnarc@bih.net.ba]
Pascal MELIN	CHG Saint Dizier, Saint Dizier, France, EU Saint Dizier, France, EU - [E-Mail: pascalmelin@hotmail.fr]
Fadi MEROUEH	Health Without Barriers, France, EU - [E-Mail: fadimeroueh@gmail.com]
Joelle MICALLEF	Addictovigilance, , Marseille, France, EU - [E-Mail: joelle.micallef@ap-hm.fr]
Luke MITCHESON	South London and Maudsley NHS Foundation Trust, London, UK - [E-Mail:
Linda MONTANARI	EMCDDA, Lisbon, Portugal, EU - [E-Mail: Linda.Montanari@emcdda.europa.eu]
Ivan MONTOYA	Division of Therapeutics and Medical Consequences (DTMC), NIDA, , Rockville, Maryland, USA - [E-Mail: imontoya@mail.nih.gov]
Kim MUESER	Center for Psychiatric Rehabilitation,, Boston, MA, USA - [E-Mail: mueser@bu.edu]
Vijay NADIPELLI	Indivior Inc., Richmond, VA , USA, Richmond, VA , USA - [E-Mail: vijay.nadipelli@indivior.com]
Kalia NIKOLAU	University of Cyprus, Limassol, Cyprus, EU, Limassol, Cyprus, EU - [E-Mail: kalianikolaou2@gmail.com]
Walter PAGANIN	Department of Mental Health ASL RM/5, Tivoli (RM), Italy, EU - [E-Mail: 63walter@gmail.com]
Pier Paolo PANI	Social-Health Services, Health District USL Cagliari, Italy, EU - [E-Mail: pallolo@tin.it]
Mark PARRINO	Americam Association for the Treatment of Opioid dependence, New York, New York, USA - [E-Mail: mark.parrino@aatod.org]
Lucie PENNEL	Service Universitaire de Pharmaco-Addictologie-CSAPA, CHU Grenoble Alpes, Saint-Martin d'Hères, France, EU - [E-Mail: LPennel@chu-grenoble.fr]
Marc REISINGER	European Opioid Addiction Treatment Association, Brussels, Belgium, EU - [E-Mail: m.reisinger@proximus.be]
Marco RIGLIETTA	Addiction Medicine Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy, EU - [E-Mail: mriglietta@asl.bergamo.it]
Paola ROSCA	National Supervisor, Dept for the Treatment of Substance Abuse Ministry of Health, Jerusalem, Israel - [E-Mail: Paola.Roska@moh.gov.il]
Perrine ROUX	Aix Marseille University, INSERM, IRD, SESSTIM, ORS PACA, Observatoire régional de la santé Provence-Alpes-Côte d'Azur, Marseille, France, EU - [E-Mail: perrine.roux@inserm.fr.]
Nusa SEGREC	Center for treatment of drug addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU - [E-Mail: nusa.segrec@psih-klinika.si]

Gabriel SHAYA	Indivior, Slough, UK - [E-Mail: naomi.dingwall@indivior.com]
Olivier SIMON	Centre du Jeu Excessif, CHUV, Lausanne Et Collège Romand de Médecine de L'addiction, Lausanne, France - [E-Mail: Olivier.Simon@chuv.ch]
Lorenzo SOMAINI	Drug Addiction Unit, Biella, Italy, EU - [E-Mail: Lorenzo.Somaini@aslbi.piemonte.it]
Tsvetana STOYKOVA	The Kantchelov Clinic Sofia, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Sir John STRANG	National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, London UK - [E-Mail: john.strang@kcl.ac.uk]
Nestor SZERMAN	Complutense University of Madrid, Spain, EU, Madrid, Spain, EU - [E-Mail: nszermanb@gmail.com]
Lars TANUN	Oslo University Hospital, , Oslo, Norway - [E-Mail: lars.tanum@ahus.no]
Robert TELTZROW	Consultant Pompidou Group of the Council of Europe, Paris, France, EU - [E-Mail: Robert.TELTZROW@coe.int]
Maria Giovanna TOCCO	Indivior Italia, Milan, Italy, EU - [E-Mail: giovanna.tocco@indivior.com]
Marta TORRENS	Addiction Unit, Institute of Psychiatry and Addictions, Hospital del Mar-IMIM, University of Barcelona, Barcelona, Catalonia, Spain, EU - [E-Mail: mtorrens@parcdesalutmar.cat]
Joan TRUJOLS	Hospital de la Santa Cruz and Sant Pau / Sant Pau Biomedical Research Institute (IIB Sant Pau) / CIBER Mental Health (CIBERSAM), Barcelona, Catalonia, Spain, EU - [E-Mail: jtrujols@santpau.cat]
Albrecht ULMER	Institute for addiction research, Stuttgart, Germany, EU - [E-Mail: albrecht.ulmer@gmx.de]
Gabriel VALLECILLO	Institute of Neuropsychiatry and Addictions (INAD). Hospital del Mar Medical Research Institute-IMIM, Autonomous University of Barcelona, Catalonia, Spain, EU - [E-Mail: gvallecillo@parcdesalutmar.cat]
Jorn Henrik VOLD	Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway, Bergen, Norway - [E-Mail: jorn.henrik.vold@helse-bergen.no]
Maren Wright VOSS	Utah State University Extension, South Jordan, UT, USA, Salt Lake City, UT, USA - [E-Mail: maren.voss@usu.edu]
Gabrielle Katrine WELLE-STRAND	Norwegian Centre for Addiction Research (Seraf), University of Oslo, Oslo, Norway - [E-Mail: gabwel@online.no]
Daniele ZULLINO	Service d'addictologie des hôpitaux universitaires de Genève et Collège romand de médecine de l'addiction, Geneve, Switzerland - [E-Mail: daniele.zullino@hcuge.ch]



CHIMERA AWARD

European Opiate Addiction Treatment Association Award

"The Alessandro Tagliamonte Award"



"Dedicated to all those who dream of a better world for drug addicts"

FORMER RECIPIENTS:

Marc Auriacombe (France) - 2002	Vladimir Mendelevich (Russia) - 2014
Olof Blix (Sweden) - 2000	Lubomir Okruhlica (Slovak Republic) - 2002
Miguel Casas (Spain) - 2012	Matteo Pacini (Italy) - 2018
Thomas Clausen (Norway) - 2014	Pier Paolo Pani (Italy) - 2004
Pascal Courty (France) - 2012	Luis Patricio (Portugal) - 2010
Jean-Jacques Deglon (Switzerland) - 2004	Einat Peles (Israel) - 2016
Maurice Dematteis (France) - 2018	Slavko Sakoman (Croatia) - 2010
Sergey Dvoryak (Ukraine) - 2010	Lorenzo Somaini (Italy) - 2014
Gabriele Fischer (Austria) - 2008	Marta Torrens (Spain) - 2006
Gilberto Gerra (Italy) - 2006	Didier Touzeau (France) - 2008
Ante Ivancic (Croatia) - 2006	Ambros Uchtenhagen (Switzerland) - 2016
Alexander Kantchelov (Bulgaria) - 2004	Peter Vossenbergh (The Netherlands) - 2016
Andrej Kastelic (Slovenia) - 2008	Helge Waal (Norway) - 2012
Mercedes Lovrecic (Slovenia) - 2002	Gabrielle Welle-Strand (Norway) - 2018

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016	Robert Newman (USA) - 2012
Loretta Finnegan (USA) - 2010	Marc Reisinger (Belgium) - 2004
Mary Jeanne Kreek (USA) - 2014	Mark Parrino (USA) - 2018
Joyce Lowinson (USA) - 2007	Alessandro Tagliamonte (Italy) - 2004
Icro Maremmani (Italy) - 2004	



ROVAI SCHOLARS AWARD

PISA-School of Clinical and Experimental Psychiatry
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)

"The Luca Rovai Award"



"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Experimental and Clinical Psychiatry Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Experimental and Clinical Psychiatry and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Maremmani. *Poster presented at New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives* Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R.V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen. *Poster presented at 2° World Congress of the World Association on Dual Disorders (WADD), Florence, October 25-27 2018*

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tripodi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi. *Poster presented at Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders, Pisa, Italy, EU, July, 8-9 2019*

PLATINUM SPONSORS

Camurus
Indivior
Molteni

camurus

INDIVIOR
Focus on you.



MOLTENI
FARMACEUTICI

BRONZE SPONSOR

Bouchara-Recordati

OTHER SPONSOR

Ethypharm

Under the Patronage of

World Federation for the Treatment of Opioid Dependence,
New York, NY, USA

University of Grenoble, France, EU

Fédération Française d'Addictologie

Mission interministérielle de lutte contre les drogues et les
conduites addictives
Fédération Addiction



UNIVERSITÉ
Grenoble
Alpes



Mission interministérielle
de lutte contre les drogues
et les conduites addictives
drogues.gouv.fr



FÉDÉRATION
ADDITION